944265-88-7
Chemical Structure
BrP-LPA sodium
- CAS. Nr.: 944265-88-7
- Formula:C20H39BrNaO6P
- Molecular Weight:509.39
IUPAC Name: 2-(7-(tert-butyl)pyren-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
InChIKey: XCUPLWPVEJCIBO-HMEPSURWSA-M
SMILES: O=P(O)(O[Na])C(Br)C[C@H](O)COC(CCCCCCCCCCCCCCC)=O
Biological Activity: BrP-LPA sodium is a pan-opposite agent for lysophosphatidic acid (LPA). It has antagonistic activity against LPA1 (IC50 = 4520 nM), LPA2 (IC50 = 468 nM), LPA3, and LPA4. BrP-LPA sodium also has partial agonistic activity for LPA5, with its EC50 being 1282 nM. BrP-LPA sodium has ATX inhibitory activity. BrP-LPA sodium effectively inhibits the migration and invasion of breast cancer cells. BrP-LPA sodium achieves tumor regression and anti-angiogenesis in mice breast cancer xenograft model. BrP-LPA sodium can be used for the study of breast cancer[1].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BrP-LPA sodium | BrP-LPA sodium is a pan-opposite agent for lysophosphatidic acid (LPA). It has antagonistic activity against LPA1 (IC50 = 4520 nM), LPA2 (IC50 = 468 nM), LPA3, and LPA4. BrP-LPA sodium also has partial agonistic activity for LPA5, with its EC50 being 1282 nM. BrP-LPA sodium has ATX inhibitory activity. BrP-LPA sodium effectively inhibits the migration and invasion of breast cancer cells. BrP-LPA sodium achieves tumor regression and anti-angiogenesis in mice breast cancer xenograft model. BrP-LPA sodium can be used for the study of breast cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
